Peptides for the treatment of covid-19
Compositions for inhibiting the binding between ACE2 and SARS-CoV-2 spike S1 are disclosed. Methods of treating COVID-19 are disclosed. Methods of making an in vivo model of COVID-19 are also disclosed.
1. A composition comprising an isolated peptide that inhibits the association between SARS-CoV-2 spike S1 and Angiotensin Converting Enzyme-2 (ACE-2) without inhibiting the activity of ACE-2, wherein the isolated peptide consists of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7, or SEQ ID NO: 9.
2. The composition according to claim 1 , wherein the peptide consists of SEQ ID NO: 5.
3. The composition according to claim 1 , wherein the peptide consists of SEQ ID NO: 6.
4. The composition according to claim 1 , wherein the peptide consists of SEQ ID NO: 7.
5. The composition according to claim 1 , wherein the peptide consists of SEQ ID NO: 9.
6. The composition according to claim 1 , wherein the peptide consists of SEQ ID NO: 3.
7. The composition according to claim 1 , wherein the peptide consists of SEQ ID NO: 4.
8. The composition according to claim 1 , comprising two or more isolated peptides selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 9.
9. The composition according to claim 1 , wherein the composition further comprises a cell penetrating peptide of SEQ ID NO: 13 joined to the N-terminus or the C-terminus of the isolated peptide.
10. A method of alleviating the symptoms associated with COVID-19, the method comprising administering a first agent to a subject in need thereof, the first agent comprising an isolated peptide that inhibits the association between SARS-CoV-2 spike S1 and Angiotensin Converting Enzyme-2 (ACE-2) without inhibiting the activity of ACE-2, wherein the isolated peptide is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO:7, and SEQ ID NO: 9.
11. The method according to claim 10 , wherein first agent comprises two or more peptides selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 9.
12. The method according to claim 10 , further comprising administering a second agent.
13. The method according to claim 10 , wherein first agent is delivered nasally or by inhalation.
14. The method according to claim 12 , wherein the second agent is delivered systemically.
15. A method of halting the further progression of or worsening of the symptoms associated with COVID-19, the method comprising administering a first agent to a subject in need thereof, the first agent comprising an isolated peptide that inhibits the association between SARS-CoV-2 spike S1 and Angiotensin Converting Enzyme-2 (ACE-2) without inhibiting the activity of ACE-2, wherein the isolated peptide is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 9.
16. The method according to claim 15 , wherein the first agent comprises two or more peptides selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 9.
17. The method according to claim 15 , further comprising administering a second agent.
18. The method according to claim 15 , wherein the first agent is delivered nasally or by inhalation.
19. The method according to claim 17 , wherein the second agent is delivered systemically.